Program Type: New England CEPAC

Intervontions of Interest: Monoclonal Antibodies natalizumab (Tysabri®, Biogen) ofatumumab (Kesimpta®, Novartis) ocrelizumab (Ocrevus®, Genentech) rituximab (Rituxan®, Genentech, and biosimilars) ublituximab (TG Therapeutics)  Oral Therapies dimethyl fumarate (Tecfidera®, Biogen, and generics) diroximel fumarate (Vumerity®, Biogen) monomethyl fumarate (Bafiertam®, Banner Life Sciences) fingolimod (Gilenya®, Novartis) ozanimod (Zeposia®, Bristol Myers Squibb) ponesimod (Ponvory®, Janssen) siponimod (Mayzent®, Novartis) teriflunomide […]

Interventions of Interest: subcutaneous semaglutide (Wegovy®, Novo Nordisk) phentermine/topiramate (Qsymia, Vivus Pharmaceuticals) naltrexone/bupropion (Contrave, Currax Pharma) liraglutide (Saxenda®, Novo Nordisk) Obesity is an increasingly common chronic condition that is associated with increased risk of chronic diseases such as diabetes, cancer, and heart disease. Individuals who are overweight or those with obesity face considerable social stigma […]

Interventions of Interest: betibeglogene autotemcel (bluebird bio) The independent appraisal committee unanimously determined that the evidence is adequate to demonstrate that beti-cel provides a net health benefit compared to standard clinical management. Given the high costs of standard care, cost-effectiveness modeling finds beti-cel meets commonly accepted value thresholds at an anticipated price of $2.1 million […]

Interventions of Interest: tirzepatide (Mounjaro™, Eli Lilly) Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as an add-on type 2 diabetes therapy; tirzepatide would achieve common thresholds for cost-effectiveness if priced between $5,500 – $5,700 per year.  At the January 20 virtual meeting, ICER’s independent appraisal committee […]

Interventions of Interest: Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.) Efgartigimod (Vyvgart™, argenx) The independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a net health benefit when compared to conventional therapy alone. According to ICER’s health-benefit price benchmark, eculizumab would need to be priced between $13,200 – $19,400 to be […]

Interventions of Interest: abrocitinib (Cibinqo®, Pfizer) tralokinumab (Adtralza®, LEO Pharma) baricitinib (Olumiant®, Eli Lilly, Incyte Corporation) upadacitinib (Rinvoq®, AbbVie) ruxolitinib (Opzelura™, Incyte Corporation) Atopic dermatitis is a chronic relapsing skin condition associated with dry skin and itching. It is characterized by acute flare-ups of pruritic lesions over dry skin. Atopic dermatitis is a subset of […]

Interventions of Interest: Brachytherapy and Proton beam therapy for prostate cancer. Prostate cancer is the second leading cause of cancer deaths and the seventh overall causeof death in men in the United States (Centers for Disease Control and Prevention, 2008).Given that most new cases are diagnosed at an early, localized stage, significant attentionhas been focused […]

Intervention of interest: Insulin degludec (Tresiba®, Novo Nordisk A/S). The Centers for Disease Control and Prevention (CDC) estimates that 29.1 million Americans have diabetes and 1.7 million adults are newly diagnosed with diabetes mellitus (DM) each year. To treat diabetes, approximately 6 million Americans use insulin therapy as part of their treatment plan to control […]